![]() |
市場調查報告書
商品編碼
2088887
眼底攝影機市場:2026-2032年全球市場預測(按技術、產品類型、分銷管道、應用和最終用戶分類)Fundus Cameras Market by Technology, Product Type, Distribution Channel, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,眼底攝影機市場將成長至 6.0432 億美元,複合年成長率為 5.24%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 4.2266億美元 |
| 預計年份:2026年 | 4.4645億美元 |
| 預測年份 2032 | 6.0432億美元 |
| 複合年成長率 (%) | 5.24% |
眼底攝影機正逐漸成為眼科、驗光師、內分泌科醫生、初級基層醫療以及主導遠端醫療眼科檢查的核心診斷工具。這些系統能夠捕捉視網膜、視神經乳頭、黃斑部和視網膜血管的高解析度影像,有助於檢測和後續觀察糖尿病視網膜病變、青光眼、老齡化黃斑部病變、高血壓性視網膜病變、視網膜血管疾病以及其他威脅視力的疾病。
眼底攝影機領域正從以醫院為中心的影像診斷模式轉向分散式、網路化和整合的眼科檢查工作流程。無需散瞳、可攜式且兼容智慧型手機的眼底攝影機,使其能夠在專科診所以外使用。這使得視網膜成像可以在基層醫療診所、藥房、糖尿病診所、社區健康計畫和行動篩檢車上進行。
人工智慧 (AI) 透過將視網膜影像轉化為可操作的臨床訊號,從根本上改變了眼底攝影機的價值提案。 FDA已通過核准的用於糖尿病視網膜病變篩檢的自主 AI 系統(包括 2018 年核准的突破性自主診斷系統)已檢驗,只要影像品質、演算法效能和臨床管治得到驗證,AI 驅動的視網膜評估即可在非專科醫療機構中實施。
亞太地區是成長最快的地區之一,這主要得益於該地區糖尿病患者數量眾多、眼科醫療基礎設施不斷完善、人口老化以及政府對社區篩檢的重視。儘管中國、印度、日本、韓國、澳洲和東協等市場的成長率不盡相同,但通用的需求促進因素是都市區醫院、糖尿病診所和醫療資源匱乏的農村地區對視網膜影像診斷的普及。該地區也受益於數位醫療基礎設施的不斷完善,但價格、培訓要求和售後服務仍然是採購的關鍵因素。
隨著各國政府和私人醫療機構在應對日益嚴重的糖尿病問題的同時,不斷擴大基層醫療體系並部署行動篩檢,東協市場對攜帶式和中端眼底攝影機極具吸引力。海灣合作理事會(GCC)成員國糖尿病負擔沉重,積極投資醫院建設,並迅速普及數位醫療,這些都為高階成像系統、雲端工作流程以及符合各國預防性醫療戰略的人工智慧篩檢模式提供了有利環境。
由於美國食品藥物管理局 (FDA) 的先例、大規模的糖尿病護理網路、廣泛的眼科服務以及保險公司對預防性品質指標的重視,美國在人工智慧視網膜篩檢的採用方面處於主導地位。另一方面,加拿大則強調提供綜合公共衛生服務、省級主導的護理路徑以及在都市區、農村和偏遠社區實現公平的醫療服務取得。在墨西哥和巴西,隨著私人眼科網路、糖尿病管理計畫和都市區專科醫療中心的出現,對人工智慧視網膜篩檢的需求正在成長,但可及性、價格、培訓和設備耐用性仍然是關鍵的購買因素。
產業領導者應優先考慮能夠提供經臨床檢驗的影像表現、簡化工作流程並降低視網膜篩檢整體成本的服務模式。產品系列應包括用於診所的非散瞳桌上型系統、用於分散式篩檢的攜帶式眼底攝影機,以及支援影像管理、報告、安全轉診工作流程和與電子健康記錄整合的軟體層。
本執行摘要採用結構化的二手研究途徑編寫,並遵循嚴格的市場研究標準。輸入資料包括來自世界衛生組織 (WHO) 和國際糖尿病聯盟 (IDF) 等組織的公共衛生資料集、來自美國食品藥物管理局(FDA) 等監管機構的資訊、已發布的臨床指南、同行評審的眼科文獻、糖尿病篩檢建議,以及醫療設備文件和醫療保健系統的檢驗資訊。
眼底攝影機市場正進入一個應用領域不斷拓展、人工智慧技術日益融合、預防性眼科護理現代化程度不斷提高的新階段。隨著糖尿病盛行率的上升以及醫療系統對視網膜疾病早期檢測需求的日益成長,眼底影像技術正從僅供專科醫生使用的工具,轉變為更廣泛應用的篩檢平台,並融入慢性病管理和社區健康促進計畫中。
The Fundus Cameras Market is projected to grow by USD 604.32 million at a CAGR of 5.24% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 422.66 million |
| Estimated Year [2026] | USD 446.45 million |
| Forecast Year [2032] | USD 604.32 million |
| CAGR (%) | 5.24% |
Fundus cameras are becoming a core diagnostic asset in ophthalmology, optometry, endocrinology, primary care, and telehealth-led eye screening. These systems capture high-resolution images of the retina, optic disc, macula, and retinal vasculature, supporting detection and monitoring of diabetic retinopathy, glaucoma, age-related macular degeneration, hypertensive retinopathy, retinal vascular disease, and other sight-threatening conditions.
Demand is supported by durable healthcare fundamentals. The World Health Organization estimates that at least 2.2 billion people live with near or distance vision impairment, while the International Diabetes Federation reported 537 million adults living with diabetes in 2021 and projected this figure to reach 643 million by 2030. Because diabetic retinopathy affects roughly one in three people with diabetes, fundus photography is increasingly positioned as a scalable tool for preventive eye care, earlier referral, longitudinal disease management, and population-level screening.
The fundus camera landscape is shifting from hospital-centered imaging toward distributed, connected, and workflow-integrated eye screening. Non-mydriatic, portable, handheld, and smartphone-enabled fundus cameras are widening access beyond specialist clinics, allowing retinal image capture in primary care offices, pharmacies, diabetes clinics, community health programs, and mobile screening units.
At the same time, buying criteria are moving beyond optical quality alone. Providers increasingly prioritize ease of use, image capture speed, field of view, image consistency, interoperability with electronic health records, cloud-based review, cybersecurity, and compatibility with artificial intelligence decision-support. This shift is reshaping competition as hardware, software, and service models converge around end-to-end retinal screening ecosystems.
Artificial intelligence is materially changing the value proposition of fundus cameras by converting retinal images into actionable clinical signals. FDA-authorized autonomous AI systems for diabetic retinopathy screening, including the landmark 2018 authorization of an autonomous diagnostic system, demonstrated that AI-enabled retinal assessment can be deployed in non-specialist care settings when image quality, algorithm performance, and clinical governance are validated.
The cumulative impact extends across the workflow. AI can assist with image quality checks, lesion detection, disease triage, report generation, and referral prioritization, helping reduce avoidable specialist burden while improving screening adherence. The most defensible opportunities will come from combining high-quality imaging hardware with clinically validated algorithms, transparent performance monitoring, bias assessment across populations, and compliance with medical device, privacy, and health data regulations.
Asia-Pacific is a high-priority growth arena because of its large diabetes population, expanding eye care infrastructure, aging demographics, and government interest in community-based screening. China, India, Japan, South Korea, Australia, and ASEAN markets are advancing at different speeds, but the shared demand driver is the need to scale retinal imaging across urban hospitals, diabetes clinics, and underserved rural regions. The region also benefits from expanding digital health infrastructure, though procurement remains highly sensitive to affordability, training requirements, and after-sales service.
North America remains a leading adoption region due to reimbursement awareness, strong ophthalmology and optometry networks, FDA-cleared AI pathways, and quality-measure pressure around diabetic eye exams. Europe benefits from organized screening programs, MDR-regulated device standards, privacy requirements, and public health emphasis on avoidable blindness. Latin America is gaining momentum through private clinic expansion, diabetes care programs, and urban specialty networks, while affordability and uneven access shape device selection. The Middle East is investing in hospital modernization, specialty care, and digital health platforms, particularly where high diabetes prevalence is a national health priority. Africa remains underpenetrated but strategically important, as portable fundus cameras and teleophthalmology can help address ophthalmologist shortages, limited screening coverage, and geographic access barriers.
ASEAN markets are attractive for portable and mid-priced fundus camera platforms as governments and private providers address rising diabetes prevalence while expanding primary care capacity and mobile screening outreach. The GCC is characterized by high diabetes burden, strong hospital investment, and rapid digital health adoption, creating favorable conditions for premium imaging systems, cloud-connected workflows, and AI-enabled screening models that align with national preventive health strategies.
The European Union is shaped by regulatory rigor, public screening pathways, cross-border privacy expectations, and demand for interoperable, clinically validated solutions. BRICS countries combine large patient pools with uneven specialist distribution, making scalable screening, portable imaging, and teleophthalmology commercially relevant. G7 markets lead in premium device adoption, evidence-based procurement, clinical validation, and AI governance, while NATO-aligned healthcare systems often emphasize cybersecurity, supply chain resilience, and standardized technology procurement for connected medical devices.
The United States leads in AI-enabled retinal screening adoption due to FDA precedent, large diabetes care networks, broad optometry access, and payer focus on preventive quality measures, while Canada emphasizes integrated public health delivery, province-led care pathways, and equitable access across urban, rural, and remote communities. Mexico and Brazil offer growing demand through private ophthalmology networks, diabetes management programs, and urban specialty centers, although access, affordability, training, and device durability remain key purchasing factors.
In Europe, the United Kingdom benefits from established diabetic eye screening infrastructure, Germany and France favor quality-certified imaging, interoperability, and regulated procurement, Italy and Spain show demand tied to aging populations and chronic disease care, and Russia continues to require broad geographic coverage solutions suitable for distributed healthcare delivery. In Asia-Pacific, China and India represent large-scale screening opportunities because of their diabetes burden and expanding care infrastructure, Japan prioritizes advanced imaging quality for aging-related retinal disease, South Korea supports technology-forward adoption through digitally mature healthcare settings, and Australia combines telehealth capability with rural and remote care needs.
Industry leaders should prioritize clinically validated imaging performance, workflow simplicity, and service models that reduce the total cost of retinal screening. Product portfolios should include non-mydriatic tabletop systems for clinics, portable fundus cameras for decentralized screening, and software layers that support image management, reporting, secure referral workflows, and integration with electronic health records.
Manufacturers should also invest in AI partnerships, regulatory evidence, real-world performance monitoring, post-market surveillance, cybersecurity-by-design, and usability improvements for non-specialist operators. Commercial teams can gain traction by aligning fundus camera deployment with diabetes care pathways, quality metrics, teleophthalmology programs, community eye screening, and public-private health initiatives. In emerging markets, affordability, training, maintenance support, local service coverage, and cloud-enabled remote interpretation will be decisive differentiators.
This executive summary is developed using a structured secondary research approach aligned with rigorous market intelligence standards. Inputs include public health datasets from organizations such as the World Health Organization and the International Diabetes Federation, regulatory information from agencies such as the U.S. Food and Drug Administration, published clinical guidance, peer-reviewed ophthalmology literature, diabetes screening recommendations, and verified information from medical device documentation and healthcare systems.
The analysis triangulates disease burden, screening needs, technology adoption, regional healthcare infrastructure, regulatory pathways, clinical workflow requirements, and digital health trends. Findings are interpreted through market relevance, clinical utility, procurement behavior, operational scalability, and compliance requirements to provide an evidence-led view of the fundus cameras market without relying on unverified claims, market sizing, market share, or forecasting.
The fundus cameras market is entering a phase defined by access expansion, AI integration, and preventive eye care modernization. As diabetes prevalence rises and healthcare systems seek earlier detection of retinal disease, fundus imaging is moving from a specialist-only tool to a broader screening platform embedded in chronic disease management and population health programs.
Winning strategies will combine reliable optics, easy image acquisition, validated AI, secure connectivity, interoperability, and strong service support. The strongest opportunities will emerge where fundus cameras are embedded into diabetes management, teleophthalmology, community screening, rural health delivery, and value-based healthcare programs focused on preventing avoidable vision loss.
TABLE 383.